Ihsanullah Shirani

Dr. Ihsanullah Shirani

Para-Clinic Department, Faculty of Veterinary Medicine, Nangarhar University, Afghanistan.
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2021 in Viruses
Verified
Journal Article
Open access
PDF file
MBMarawan Adel Marawan Basuony
Marawan Adel Marawan Basuony
Abdulaziz AlouffiAbdulaziz Alouffi
Abdulaziz Alouffi
STSuleiman El Tokhy
Suleiman El Tokhy
SBSara Badawy
Sara Badawy
Ihsanullah ShiraniIhsanullah Shirani
Ihsanullah Shirani
Abdelfattah SelimAbdelfattah Selim
Abdelfattah Selim
Bovine leukaemia virus (BLV) is a deltaretrovirus that is closely related to human T-cell leukaemia virus types 1 and 2 (HTLV-1 and -2). It causes enzootic bovine leukosis (EBL), which is the most important neoplastic disease in cattle. Most BLV-infected cattle are asymptomatic, which potentiates extremely high shedding rates of the virus in many cattle populations. Approximately 30% of them show persistent lymphocytosis that has various clinical outcomes; only a small proportion of animals (less than 5%) exhibit signs of EBL. BLV causes major economic losses in the cattle industry, especially in dairy farms. Direct costs are due to a decrease in animal productivity and in cow longevity; indirect costs are caused by restrictions that are placed on the import of animals and animal products from infected areas. Most European regions have implemented an efficient eradication programme, yet BLV prevalence remains high worldwide. Control of the disease is not feasible because there is no effective vaccine against it. Therefore, detection and early diagnosis of the disease are essential in order to diminish its spreading and the economic losses it causes. This review comprises an overview of bovine leukosis, which highlights the epidemiology of the disease, diagnostic tests that are used and effective control strategies.

13 May 2022 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
ADAli Dawood
Ali Dawood
SASamah Attia Algharib
Samah Attia Algharib
GZGang Zhao
Gang Zhao
TZTingting Zhu
Tingting Zhu
MQMingpu Qi
Mingpu Qi
aizhen guoaizhen guo
aizhen guo
Mycoplasmas as economically important and pantropic pathogens can cause similar clinical diseases in different hosts by eluding host defense and establishing their niches despite their limited metabolic capacities. Besides, enormous undiscovered virulence has a fundamental role in the pathogenesis of pathogenic mycoplasmas. On the other hand, they are host-specific pathogens with some highly pathogenic members that can colonize a vast number of habitats. Reshuffling mycoplasmas genetic information and evolving rapidly is a way to avoid their host’s immune system. However, currently, only a few control measures exist against some mycoplasmosis which are far from satisfaction. This review aimed to provide an updated insight into the state of mycoplasmas as pathogens by summarizing and analyzing the comprehensive progress, current challenge, and future perspectives of mycoplasmas. It covers clinical implications of mycoplasmas in humans and domestic and wild animals, virulence-related factors, the process of gene transfer and its crucial prospects, the current application and future perspectives of nanotechnology for diagnosing and curing mycoplasmosis, Mycoplasma vaccination, and protective immunity. Several questions remain unanswered and are recommended to pay close attention to. The findings would be helpful to develop new strategies for basic and applied research on mycoplasmas and facilitate the control of mycoplasmosis for humans and various species of animals.

21 September 2020 in Pathogens
Verified
Journal Article
Open access
PDF file
Ihsanullah ShiraniIhsanullah Shirani
Ihsanullah Shirani
HZHui Zhang
Hui Zhang
GZGang Zhao
Gang Zhao
SLSiyi Lu
Siyi Lu
MBMarawan Adel Marawan Basuony
Marawan Adel Marawan Basuony
aizhen guoaizhen guo
aizhen guo
Mycoplasma bovis is a major pathogen, responsible for bovine respiratory diseases worldwide. The present lack of effective control measures leaves cattle owners at considerable perpetual risk of M. bovis outbreaks. In this study, we identified M. bovis secreted immunogenic proteins in silico as potential candidates for novel diagnostic agents and vaccines. We used immunoinformatics to analyze 438 M. bovis proteins previously identified with a label-free proteomics analysis of virulent M. bovis HB0801 (P1) and its attenuated P150 strains. The subcellular localization of these proteins was preliminarily screened and 59 proteins were found to be secreted extracellular proteins. Twenty-seven of these proteins contained a large number of predictive T-cell epitopes presented by major histocompatibility complex (MHC) class I and II molecules. Twenty-two of these 27 proteins had a high number of conformational B-cell epitopes, predicted from the corresponding 3D structural templates, including one unique to P1, two unique to P150, and 19 common to both strains. Five proteins were selected for further validation, and two of these, MbovP274 and MbovP570, were successfully expressed and purified. Both were confirmed to be secretory and highly immunogenic proteins that induced a mouse antibody response, reacted with cattle serum positive for M. bovis infection, and significantly increased the production of interleukin 8 (IL-8), IL-12 and interferon γ (IFN-γ) during the secretion of these three cytokines by both M. bovis mutants of these genes. These results should be useful in the development of novel immunological agents against M. bovis infection.

28 February 2024 in Animals
Verified
Journal Article
Open access
PDF file
SZSen Zhang
Sen Zhang
GLGuoxing Liu
Guoxing Liu
WWWenying Wu
Wenying Wu
LYLi Yang
Li Yang
Ihsanullah ShiraniIhsanullah Shirani
Ihsanullah Shirani
YCYingyu Chen
Yingyu Chen
Bovine respiratory disease (BRD) is one of the most common diseases in the cattle industry; it is a globally prevalent multifactorial infection primarily caused by viral and bacterial coinfections. In China, Mycoplasma bovis (M. bovis) and bovine herpesvirus type 1 (BoHV-1) are the most notable pathogens associated with BRD. Our previous study attempted to combine the two vaccines and conducted a preliminary investigation of their optimal antigenic ratios. Based on this premise, the research extended its investigation by administering varying vaccine doses in a rabbit model to identify the most effective immunization dosage. After immunization, all rabbits in other immunization dose groups had a normal rectal temperature without obvious clinical symptoms. Furthermore, assays performed on the samples collected from immunized rabbits indicated that there were increased humoral and cellular immunological reactions. Moreover, the histological analysis of the lungs showed that immunized rabbits had more intact lung tissue than their unimmunized counterparts after the challenge. Additionally, there appears to be a positive correlation between the protective efficacy and the immunization dose. In conclusion, the different immunization doses of the attenuated and marker M. bovis HB150 and BoHV-1 gG-/tk- combined vaccine were clinically safe in rabbits; the mix of 2.0 × 108 CFU of M. bovis HB150 and 2.0 × 106 TCID50 BoHV-1 gG-/tk- strain was most promising due to its highest humoral and cellular immune responses and a more complete morphology of the lung tissue compared with others. These findings determined the optimal immunization dose of the attenuated and marker M. bovis HB150 and BoHV-1 gG-/tk- combined vaccine, laying a foundation for its clinical application.

1 September 2020 in Advances in Animal and Veterinary Sciences
Verified
Journal Article
Open access
Ihsanullah ShiraniIhsanullah Shirani
Ihsanullah Shirani
MMMarawan A. Marawan
Marawan A. Marawan
NRNajibullah Rahimi
Najibullah Rahimi
ADAli Dawood
Ali Dawood
| Clostridium difficile is an important emerging infectious agent and might colonize in digestive tract of humans. C. difficile exhibits a low level of gene conservation. Consequently, antibiotic therapy result has demonstrated in 15-30% cases. In the current review we summarized up to date information about the drug resistance genotypes of C. difficile for the first time. Our study revealed that there was a steady difference among various genotype. Which demonstrated that mutations in the DNA genes was very common in the antibiotic resistance phenotypes. Together our data revealed that antibiotic resistivity poses selective pressure on the genome of C. difficile that could lead to more adoptable drug resistance strains. This study may open a new avenue for the research in understanding the mechanism of C. difficile adaptation to antibiotics and the development of new antibacterial. However, their further research is needed to exploring C. difficile genomic diversity changed from molecular typing assays to total-genome sequence comparisons and comparative genome microarrays.

3 November 2021
Verified
Book Chapter
Closed access
Ihsanullah ShiraniIhsanullah Shirani
Ihsanullah Shirani
MMMarawan A. Marawan
Marawan A. Marawan
NRNajibullah Rahimi
Najibullah Rahimi
ADAli Dawood
Ali Dawood
AGAizhen Guo
Aizhen Guo
Clostridium difficile is an important emerging infectious agent, and might colonize in digestive tract of animals and humans. C. difficile exhibits a low level of gene conservation. Consequently, antibiotic therapy has demonstrated in 15-30% effectiveness of the cases. In the current review we summarized up to date information about the drug resistance genotypes of C. difficile for the first time, including sporulation and motility methods, growth suitability, antibiotic susceptibility, and whole-genome sequencing. PCR enables to certify the recurrences were a mixture of original (relapse) and new strains (reinfection). Our study revealed that there was a steady difference among various genotypes, demonstrating that mutations in the DNA genes were common in the antibiotic resistance phenotypes. Together our data revealed that antibiotic resistance poses selective pressure on the genome evolution of C. difficile that could lead to more adoptable strains with drug resistance. This study may open a new avenue for the research in understanding the mechanism of C. difficile adaptation to antibiotics and development of new antibacterial drugs. However, further research is needed to explore C. difficile genomic diversity changed from molecular typing assays to total-genome sequence comparisons, and comparative genome microarrays.